Long-Acting Injectable Cabotegravir and Rilpivirine in Observational Cohortstudies: A Systematic Review on Virological Failure, Resistance, and Re-Suppression Outcomes in Virallysuppressed Individuals Living with HIV.

Abstract

Background: Randomised controlled trial evidence suggests LA-I CAB+RPV has similar virological failure (VF) rates to daily oral therapy, but resistance is more common. Integrase inhibitor (INI) resistance is of particular concern and may limit future regimen choices. The optimal regimen post-selection is uncertain. Clinical practice evidence is lacking.